EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies

Christian T Meyer iD, Brianna N Smith, Jing Wang, Kevin B Teuscher iD, Brian C Grieb iD, Gregory C Howard iD, Alexander J Silver iD, Shelly L Lorey, Gordon M Stott iD, William J Moore iD, Taekyu Lee, Michael R Savona und 5 weitere

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2408889121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Christian T Meyer und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular, Cellular, and Developmental Biology, University of Colorado Boulder, Boulder, CO 80309. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), NCI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

WD40 Repeat Domain 5 (WDR5) is a highly conserved nuclear protein that recruits MYC oncoprotein transcription factors to chromatin to stimulate ribosomal protein gene expression. WDR5 is tethered to chromatin via an arginine-binding cavity known as the “WIN” site. Multiple pharmacological inhibitors of the WDR5-interaction site of WDR5 (WINi) have been described, including those with picomolar affinity and oral bioavailability in mice. Thus far, however, WINi have only been shown to be effective against a number of rare cancer types retaining wild-type p53. To explore the full potential of WINi for cancer therapy, we systematically profiled WINi across a panel of cancer cells, alone and in combination with other agents. We report that WINi are unexpectedly active against cells derived from both solid and blood-borne cancers, including those with mutant p53. Among hematologic malignancies, we find that WINi are effective as a single agent against leukemia and diffuse large B cell lymphoma xenograft models, and can be combined with the approved drug venetoclax to suppress disseminated acute myeloid leukemia in vivo. These studies reveal actionable strategies for the application of WINi to treat blood-borne cancers and forecast expanded utility of WINi against other cancer types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsXenograft Model Antitumor AssaysHumansAnimalsMiceCell Line, TumorSulfonamidesAntineoplastic AgentsTumor Suppressor Protein p53Bridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

WDR5cancer therapylymphomaribosomesvenetoclax

Substanzen

SulfonamidesvenetoclaxAntineoplastic AgentsTumor Suppressor Protein p53Bridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Molecular, Cellular, and Developmental Biology, University of Colorado Boulder, Boulder, CO 80309.
  • Duet BioSystems, Nashville, TN 37212.
  • Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232.
  • Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232.
  • Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240.

ORCID-Profile: Christian T Meyer, Kevin B Teuscher, Brian C Grieb, Gregory C Howard, Alexander J Silver, Gordon M Stott, William J Moore, April M Weissmiller, Qi Liu, Vito Quaranta, Stephen W Fesik, William P Tansey

Förderung

  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • NCI NIH HHS
  • NIDDK NIH HHS
  • HHS | NIH | National Cancer Institute (NCI)
  • NIAID NIH HHS
  • NEI NIH HHS
  • NCRR NIH HHS
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Zitieren

APA

Meyer, C. T., Smith, B. N., Wang, J., Teuscher, K. B., Grieb, B. C., Howard, G. C., Silver, A. J., Lorey, S. L., Stott, G. M., Moore, W. J., Lee, T., Savona, M. R., Weissmiller, A. M., Liu, Q., Quaranta, V., Fesik, S. W., & Tansey, W. P. (2024). Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2408889121

Vancouver

Meyer CT, Smith BN, Wang J, Teuscher KB, Grieb BC, Howard GC, et al. Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2408889121

BibTeX
@article{Meyer2024,
  author = {Meyer, Christian T and Smith, Brianna N and Wang, Jing and Teuscher, Kevin B and Grieb, Brian C and Howard, Gregory C and Silver, Alexander J and Lorey, Shelly L and Stott, Gordon M and Moore, William J and Lee, Taekyu and Savona, Michael R and Weissmiller, April M and Liu, Qi and Quaranta, Vito and Fesik, Stephen W and Tansey, William P},
  title = {Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2408889121}
}
Kostenlos starten →